Cat. No.: HY-P0004

Lysipressin

(Synonyms: Lysine vasopressin; [Lys8]-Vasopressin)

2 Cited Publications

Avis client

Based on 2 publication(s) in Google Scholar

Lysipressin (Lysine vasopressin ; [Lys8]-Vasopressin ) is a neurohypophyseal nonapeptide with dual cardiovascular regulatory activities of peripheral pressor action and central hypotensive action, and it also regulates pain perception in the body. Lysipressin is an Oxytocin Receptor agonist, with a K_i value of 10.2 nM for porcine OT receptor. Lysipressin stimulates contraction of rabbit bladder smooth muscle via V1-vasopressin receptor. The central hypotensive effect of Lysipressin depends on the sympathetic tone pathway. Lysipressin dose-dependently prolongs tail-flick latency in rats, producing a stable central antinociceptive effect. Lysipressin can be used in studies related to cardiovascular regulation, hypertension and pain.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.22%
CAS No.: 50-57-7
Formule: C₄₆H₆₅N₁₃O₁₂S₂
Masse moléculaire:1056.22

Stockage:

Sealed storage, away from moisture.

Powder -80°C, 2 years , -20°C, 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Lysipressin Chemical Structure

CAS No.: 50-57-7

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- In Vitro
- In Vivo
Chemical Information
Publications (2)
Solvant et solubilité
- In Vitro
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Voir tous les produits spécifiques à Isoform Endogenous Metabolite :

Voir tous les produits spécifiques à Isoform Vasopressin Receptor :

In Vitro

Lysipressin (LVP) enhances the contractile capacity of uterine muscle strips from luteal-phase and prepartum pigs in a dose-dependent manner by activating oxytocin receptors, with EC₅₀ values of 0.392 μM and 0.223 μM, respectively; it also increases intracellular Ca²⁺ concentrations in prepartum porcine uterine myocytes, with an EC₅₀ of 28.2 nM^[1].
Lysipressin dose-dependently displaces [³H]oxytocin binding sites on myometrial membranes of luteal-phase pigs, with a K_i value of 10.2 nM, indicating its high affinity for oxytocin receptors^[1].
Lysipressin (LVP) stimulates the contraction of bladder smooth muscle from male New Zealand white rabbits in vitro, with a mean pD₂ value of 8.4^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Lysipressin (Lysine vasopressin) (0.01-100 μ/kg; intravenous injection; single 5-second injection; intracisternal injection; single 5-second injection) induces dose-dependent peripheral pressor responses and bradycardia, as well as dose-dependent central hypotensive responses with minimal heart rate changes in anesthetized normotensive dogs^[3].
Lysipressin (1.0-10.0 μ/kg; intravenous injection; single 5-second injection; intracisternal administration; single 5-second injection) loses central hypotensive activity in anesthetized dogs after Guanethidine (HY-B1251) pretreatment, whereas its peripheral vasopressor effect stays unaltered^[3].
Lysipressin (150-500 ng; intracerebroventricular injection; single administration) produces significant, dose-dependent analgesic effects in the radiant heat tail-flick test^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Mongrel dogs (either sex, 7-13 kg, pretreated with guanethidine 15 mg/kg i.v. 24 h prior, anaesthetized with α-chloralose)^[3]
Dosage:

1.0, 10.0 mu/kg
Administration:

i.v.; single 5-second injection; intracisternal; single 5-second injection
Result:

Raised systolic and diastolic blood pressure markedly at intravenous 1.0 and 10.0 mu/kg.
Evoked bradycardia at intravenous 10.0 mu/kg.
Produced no meaningful shifts in blood pressure or heart rate at intracisternal 1.0 and 10.0 mu/kg.

Animal Model:

Mongrel dogs (either sex, 7-13 kg, anaesthetized with α-chloralose)^[3]
Dosage:

0.01, 0.1, 1.0, 10, 100 mu/kg
Administration:

i.v.; single 5-second injection; intracisternal; single 5-second injection
Result:

Elevated systolic and diastolic blood pressure dose-dependently with prominent effects.
Triggered dose-dependent bradycardia with notable heart rate reduction at 10.0 and 100.0 mu/kg.
Reduced blood pressure dose-dependently at doses ≤10 mu/kg.
Slowed heart rate significantly solely at intracisternal 0.1 mu/kg.

Animal Model:

Sprague-Dawley (female, 250-350 g)^[4]
Dosage:

150 ng; 500 ng (i.c.v.)
150 ng; 500 ng; 1500 ng (s.c.)
Administration:

i.c.v.; single dose; infused at 1 μl/15 sec; s.c.; single dose; 1 mL/kg
Result:

Significantly increased tail-flick latencies by 24% at 15 minutes post-injection (150 ng i.c.v.).
Significantly increased tail-flick latencies by 37-58% at 5, 10, and 15 minutes post-injection, respectively (500 ng i.c.v.).

Chemical Information

CAS No. 50-57-7
Appearance Solid
Masse moléculaire 1056.22
Formule C₄₆H₆₅N₁₃O₁₂S₂
Color White to off-white
Synonyms

Lysine vasopressin; [Lys8]-Vasopressin
Sequence

Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-NH2 (Disulfide bridge: Cys1-Cys6)
Sequence Shortening

CYFQNCPKG-NH2 (Disulfide bridge: Cys1-Cys6)
Structure Classification
- Phenols
- Monophenols
Initial Source
- Animals
pig
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (2)

All

Sort by:

Journal Impact Factor

Sci Rep

Characterization of five novel vasopressin V2 receptor mutants causing nephrogenic diabetes insipidus reveals a role of tolvaptan for M272R-V2R mutation. [Abstract]

2020 Oct 2;10(1):16383. PMID: 33009446
Research Square Preprint

2020 Mar 27.

Solvant et solubilité

In Vitro:

H₂O : ≥ 100 mg/mL (94.68 mM)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

0.9468 mL

4.7339 mL

9.4677 mL

5 mM

0.1894 mL

0.9468 mL

1.8935 mL

10 mM

0.0947 mL

0.4734 mL

0.9468 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (282 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Yu H, et al. Lysine Vasopressin-Induced Increases in Porcine Myometrial Contractility and Intracellular Ca²⁺ Concentrations of Myometrial Cells: Involvement of Oxytocin Receptors. Biology of Reproduction, 1995, 52: 584-590. [Content Brief]

[2]. Crankshaw D, et al. [Arg8]vasopressin-induced contractions of rabbit urinary bladder smooth muscle. European journal of pharmacology. 1989 Dec 07;173(2-3):183-8. [Content Brief]

[3]. Tran LD, et al. Effects of lysine-vasopressin and oxytocin on central cardiovascular control. British journal of pharmacology. 1982 Sep;77(1):69-73. [Content Brief]

[4]. Kordower JH, et al. Central antinociceptive effects of lysine-vasopressin and an analogue. Peptides. 1982;3(4):613-7. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O	1 mM	0.9468 mL	4.7339 mL	9.4677 mL	23.6693 mL
	5 mM	0.1894 mL	0.9468 mL	1.8935 mL	4.7339 mL
	10 mM	0.0947 mL	0.4734 mL	0.9468 mL	2.3669 mL
	15 mM	0.0631 mL	0.3156 mL	0.6312 mL	1.5780 mL
	20 mM	0.0473 mL	0.2367 mL	0.4734 mL	1.1835 mL
	25 mM	0.0379 mL	0.1894 mL	0.3787 mL	0.9468 mL
	30 mM	0.0316 mL	0.1578 mL	0.3156 mL	0.7890 mL
	40 mM	0.0237 mL	0.1183 mL	0.2367 mL	0.5917 mL
	50 mM	0.0189 mL	0.0947 mL	0.1894 mL	0.4734 mL
	60 mM	0.0158 mL	0.0789 mL	0.1578 mL	0.3945 mL
	80 mM	0.0118 mL	0.0592 mL	0.1183 mL	0.2959 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Lysipressin

2 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Lysipressin

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Peptide Compound Library

Natural Product and Natural Product-Like Compound Library

GPCR/G Protein Compound Library

Metabolism/Protease Compound Library

Natural Product Library

FDA-Approved Drug Library

Drug Repurposing Compound Library

Macrocyclic Compound Library

Anti-Cardiovascular Disease Compound Library

Phenols Library

FDA Approved & Pharmacopeial Drug Library

Peptide Library

Heterocyclic Compound Library

Off-patent Drug Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Animal-Sourced Natural Product Library

Highly Selective Activators Library

Multi-Target Compound Library

Bioactive Compound Library Max

Publications Citing Use of MedChemExpress (MCE) Lysipressin

Voir tous les produits spécifiques à Isoform Endogenous Metabolite

Voir tous les produits spécifiques à Isoform Vasopressin Receptor

Activité biologique

Chemical Information

Publications (2)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Lysipressin Related Classifications

HY-P0004 Related Classifications